Latest studies
- RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaCanada - Active not recruitingPHASE2
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
This study is looking into the long-term safety and effects of a medicine called Votoplam for people with Huntington's disease. Participants who were already in a previous study with Votoplam will continue to take it to see how it works over a longer time.
Huntington DiseaseCanada - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisCanada - Active not recruitingPHASE2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study is looking into a new medication called NS-229 for Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome. We want to see if NS-229 is safe and effective compared to a dummy treatment (placebo) when added to usual care.
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss SyndromeCanada - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Canada - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerCanada - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
Chronic Obstructive Pulmonary DiseaseCanada - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
Ovarian CancerCanada - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionCanada - RecruitingPHASE1, PHASE2
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
This study is testing a new treatment, EP-104GI, for adults with eosinophilic esophagitis (EoE). It aims to see if it's safe, how well it works, and how the body handles it. Participants will either receive the treatment or a dummy version.
Eosinophilic EsophagitisCanada - Enrolling by invitationPHASE3
Long-term Extension of GTX-102 in Angelman Syndrome
This study is looking into the long-term safety and effects of a treatment called GTX-102 for people with Angelman Syndrome. It's for those who have already been in an earlier study with this treatment.
Angelman SyndromeCanada - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerCanada - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaCanada - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskCanada - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusCanada - Active not recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
This study is testing a new medicine, zilganersen, for people with Alexander Disease. It aims to see if the medicine is safe and if it can help improve or steady movement abilities. It's a large study, comparing the medicine to a dummy treatment (placebo).
Alexander DiseaseCanada - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaCanada - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseCanada - Active not recruitingPHASE3
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
This study looks at a new drug called darolutamide, along with standard treatments like radiotherapy and hormone therapy, for men with prostate cancer that's at a very high risk of coming back. The aim is to see if this combination can better stop the cancer from spreading and improve their long-term health.
Prostate CancerCanada - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
C3GCanada - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerCanada - Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.
Primary Biliary CholangitisCanada - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaCanada - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateCanada - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaCanada - RecruitingPHASE1
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
This study is testing a new medicine, ARGX-119, for adults with a specific type of muscle weakness called DOK7-Congenital Myasthenic Syndrome (CMS). It's looking at how safe the medicine is, if it causes side effects, and if it helps people feel better.
Congenital Myasthenic SyndromeCMSCanada - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisCanada - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Canada - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsCanada - RecruitingPHASE4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
This study looks at the best time to treat a rare twin pregnancy problem called TRAP sequence. We're comparing treating it early (12-14 weeks) versus later (16-19 weeks) to see which approach works better for the healthy twin. It's a randomised trial, meaning timing is decided by chance.
Twin Reversal Arterial Perfusion SyndromeCanada - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinCanada - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesCanada - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVCanada - Active not recruitingPHASE1, PHASE2
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
This study looks at a new medicine called WVE-006 for a genetic lung and liver condition called Alpha-1 Antitrypsin Deficiency (AATD). It aims to see if the medicine is safe, how much good it does, and how the body handles it in people with AATD.
Alpha-1 Antitrypsin DeficiencyCanada - Active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
MelanomaCanada - Active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
Generalized Myasthenia GravisCanada - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisCanada - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerCanada - Active not recruitingPHASE2
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study is looking into a new medication called Bepirovirsen for people who have both HIV and long-term Hepatitis B. It will compare Bepirovirsen to a dummy treatment (placebo) to see if it's safe and effective in improving their health.
Hepatitis BCanada - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)Canada - RecruitingPHASE3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
This study looks at a new medicine called ravulizumab for adults receiving a kidney transplant from a deceased donor. It aims to see if this medicine can help their new kidney start working well faster, reducing the need for dialysis after the operation.
Delayed Graft FunctionDGFKidney TransplantCanada - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationCanada - RecruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
Hereditary angioedemaCanada - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsCanada - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaCanada - Active not recruitingNA
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This study looks at whether closing off a small part of the heart called the left atrial appendage (LAA) during heart surgery can help prevent strokes in people at risk. They're comparing it to standard care in those having heart operations.
Ischemic StrokeSystemic EmbolismCanada - Active not recruitingPHASE3
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
This study looks at a medicine called risankizumab for children aged 6 to 17 with moderate to severe psoriasis. It checks for side effects and how well the medicine works in those who were part of an earlier study. Risankizumab is already used for adults with psoriasis.
PsoriasisCanada - RecruitingNA
Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)
This study looks at whether a heart procedure called 'ablation' can better prevent serious problems like stroke or heart failure in people with an irregular heartbeat (atrial fibrillation) and other health issues, compared to standard care.
Atrial FibrillationCanada - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerCanada - RecruitingPHASE2
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This study is testing a new medicine called axatilimab for chronic graft-versus-host disease (cGVHD) in people who haven't responded well to other treatments. It will see how well axatilimab works at three different dose levels and if it’s safe to use.
Chronic Graft-versus-host-diseaseCanada